<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00959959</url>
  </required_header>
  <id_info>
    <org_study_id>TOK-200-05</org_study_id>
    <nct_id>NCT00959959</nct_id>
  </id_info>
  <brief_title>ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer</brief_title>
  <acronym>ARMOR1</acronym>
  <official_title>ARMOR1: Phase 1, Open Label, Dose Escalation Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novus Therapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novus Therapeutics, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether TOK-001 is safe and shows biological effect
      in the treatment of castration resistant prostate cancer (CRPC).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Incidence of adverse events</measure>
    <time_frame>3 months</time_frame>
    <description>Safety will be assessed by incidence of AEs and change from baseline in the following additional safety parameters: clinical laboratory assessments, physical examination, vital signs, and 12 lead electrocardiograms (ECGs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy Measures</measure>
    <time_frame>3 months</time_frame>
    <description>Efficacy will be assessed by evaluation of change in PSA level, changes from baseline in CT/MRI and bone scans, response rate RECIST criteria and additional special laboratories</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>650 mg TOK-001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1300 mg TOK-001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1950 mg TOK-001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>975 mg TOK-001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>975 mg TOK-001, supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1950 mg TOK-001, split dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2600 mg TOK-001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2600 mg TOK-001, split dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TOK-001</intervention_name>
    <description>2 capsules (325 mg each), once per day</description>
    <arm_group_label>650 mg TOK-001</arm_group_label>
    <other_name>Dose Group 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TOK-001</intervention_name>
    <description>4 capsules (325 mg each), once per day</description>
    <arm_group_label>1300 mg TOK-001</arm_group_label>
    <other_name>Dose Group 3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TOK-001</intervention_name>
    <description>6 capsules (325 mg each), once per day</description>
    <arm_group_label>1950 mg TOK-001</arm_group_label>
    <other_name>Dose Group 4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TOK-001</intervention_name>
    <description>3 capsules (325 mg each), once per day</description>
    <arm_group_label>975 mg TOK-001</arm_group_label>
    <other_name>Dose Group 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TOK-001</intervention_name>
    <description>3 capsules (325 mg each), once per day with supplement</description>
    <arm_group_label>975 mg TOK-001, supplement</arm_group_label>
    <other_name>Dose Group 5</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TOK-001</intervention_name>
    <description>6 capsules (325 mg each), split dose (3 capsules with breakfast, 3 capsules with dinner)</description>
    <arm_group_label>1950 mg TOK-001, split dose</arm_group_label>
    <other_name>Dose Group 6</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TOK-001</intervention_name>
    <description>8 capsules (325 mg each), once per day</description>
    <arm_group_label>2600 mg TOK-001</arm_group_label>
    <other_name>Dose Group 7</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TOK-001</intervention_name>
    <description>8 capsules (325 mg each), split dose (4 capsules with breakfast, 4 capsules with dinner)</description>
    <arm_group_label>2600 mg TOK-001, split dose</arm_group_label>
    <other_name>Dose Group 8</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent form

          -  Confirmed cancer of the prostate

          -  Progressing disease in spite of androgen ablation therapy

          -  Able to swallow multiple capsules

        Exclusion Criteria:

          -  Participation in another clinical trial &lt; 4 weeks prior to enrollment

          -  Metastatic disease with one or more of the following:

               -  Liver involvement

               -  Bone pain associated with confirmed evidence of metastases

               -  Non-hepatic visceral involvement

          -  The following medications:

               -  Prior treatment with MDV3100, abiraterone, Provenge or TAK700

               -  Prior treatment with ketoconazole

               -  Prior treatment with chemotherapy

               -  Prior radiation therapy completed â‰¤ 4 weeks prior to enrollment

          -  The following medical conditions:

               -  Active angina pectoris

               -  History of Hepatitis B or Hepatitis C

               -  Known HIV infection

               -  Ongoing hypertension

        Note: There are additional inclusion and exclusion criteria. The clinical site center will
        determine if you are eligible. If you are not eligible for the trial, site staff will
        detail the reasons to you.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>R. B. Montgomery, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>M. E. Taplin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Bernardino Urological Associates</name>
      <address>
        <city>San Bernardino</city>
        <state>California</state>
        <zip>92404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada &amp; US Oncology Research</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Hospital System University Medical Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington/Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2009</study_first_submitted>
  <study_first_submitted_qc>August 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2009</study_first_posted>
  <last_update_submitted>January 8, 2014</last_update_submitted>
  <last_update_submitted_qc>January 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CRPC</keyword>
  <keyword>HRPC</keyword>
  <keyword>TOK-001</keyword>
  <keyword>ARMOR</keyword>
  <keyword>ARMOR1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

